GlobalData Healthcare

Hot off the press, our team on the ground at #AAD2025 have some exciting updates to report! 🔥 Johnson & Johnson revealed highly anticipated late-breaking Phase III ICONIC-LEAD results in #psoriasis for their novel IL-23 receptor antagonist, icotrokinra, showing outstanding, robust efficacy and a favorable safety profile as a first-of-its kind oral therapy!  J&J also unveiled supportive pediatric data for Tremfya (guselkumab), the potential first-in-class anti-IL-23p19 for these patients, from the Phase III PROTOSTAR trial.  In other news, Galderma debuted their eagerly awaited commercial booth for Nemluvio, the first-in-class anti-IL-31 biologic, aiming to disrupt the fiercely competitive #atopicdermatitis space, placing rapid itch relief at the forefront with “𝘐𝘵𝘤𝘩 𝘙𝘦𝘭𝘪𝘦𝘧 *𝘤𝘭𝘪𝘤𝘬𝘴 𝘧𝘪𝘯𝘨𝘦𝘳𝘴* 𝘭𝘪𝘬𝘦 𝘵𝘩𝘢𝘵."

Are you attending #AAD2025? We'll be there, and we'd love to meet with you! Reach out to one of our analysts to arrange a time to chat. Tanuj Sircar, Managing Analyst Ash Chinyanganya, Senior Analyst Stephanie Ngan, CI Analyst Kieran Walker, CI Analyst #AtopicDermatitis #Psoriasis #AlopeciaAreata #PsoriaticArthritis

Clinical trials are becoming more expensive due to complex designs and sites in multiple countries, says GlobalData Healthcare Business Fundamentals analyst Alison Labya at Clinical Trial Supply Europe in Barcelona today. #clinicaltrials #clinicaltrialsupply #CTSEurope

Live from ECCO 2025 in Berlin! The energy is high as pharma leaders showcase groundbreaking IBD innovations.   Eli Lilly and Company’s Omvoh (mirikizumab) dominates headlines with its "NOW APPROVED FOR CD" branding, following its recent EU approval, while Pfizer spotlights Velsipity (etrasimod) as the only oral, first-line advanced therapy for UC indicated for patients 16 years of age and older.  Meanwhile, MSD’s anti-TL1A, tulisokibart, and Abivax’s RNA-based obefazimod are generating buzz in the pipeline space.  With new approvals, patient-centric solutions, and cutting-edge mechanisms of action, ECCO 2025 is shaping the future of IBD treatment.  #IBD #ECCO2025 #Innovation #Omvoh #Velsipity #Skyrizi #Tulisokibart #Obefazimod 

Exciting news from Deallus, Jack Florio will be speaking at the prestigious Drug Discovery Innovation Programme in San Diego. Bringing together top minds in drug discovery to explore the future of pharmaceutical science, #DDIP2025 offers a unique opportunity to exchange insights with key industry leaders and accelerate the pace of drug discovery. Attending DDIP? Jack would love to connect! Reach out to schedule a chat during the conference.  #DDIP #DrugDiscovery #Innovation #Biotech

Stanley Willis and Owen Jenkins-Garcia will soon be heading to Barcelona for the 26th Annual Clinical Trial Supply Europe 2025! 🚀 Drop them a message today to arrange a time to chat, or find them on the ground at Booth 52! #ClinicalTrialSupplyEurope #ClinicalTrial #SupplyChain

Are you attending #ECCO2025? We'll be there, and we'd love to meet with you! Reach out to one of our analysts to arrange a time to chat. Vasilis Roumpelakis, Managing Analyst Sumaira Malik, Senior CI Analyst Ryan Maguire, CI Analyst Edita Hamzic, CI Analyst #IBD #UC #CD

The team have touched down in San Francisco ready for #OCTWest! With regulations changing and technology growing rapidly, we can’t wait to learn more about advancing clinical developments in this space. If you’d like to meet with the team, reach out to John Rose, Kate Sandman, or Steven Muntner! #ClinicalTrials #ClinicalResearch #Biotech

FDA approves First Non-Opioid treatment for acute pain 🌟   The FDA has approved of Journavx (suzetrigine), a first-in-class non-opioid treatment for moderate to severe acute pain in adults. This groundbreaking drug works by blocking pain signals before they reach the brain, offering a safer alternative to opioids. Key Highlights: • Journavx is the first drug approved in a new class of non-opioid pain medications. • Proven to significantly reduce pain in clinical trials. • Part of the FDA's efforts to reduce opioid use and support safer pain management options. This approval is a critical step forward in providing patients with more effective and safer treatment options. 📊 GlobalData analysis from Patent Analytics tool shows the key players with publications related to “Treating Pain with Non-Opiods“.   🔗 Want to dive deeper? Check out GD Pharma Intelligence Center here https://lnkd.in/gfymRVRV Explore more here: https://lnkd.in/gVhjc8ik Not a customer? Demo with us to get access: https://lnkd.in/eB3Y_Fa ⚡ Connect with us today to explore the endless possibilities and propel your business forward! 📧 [email protected] or ☎ explore more at our contact page: https://lnkd.in/gSiqRwYh #Journavx #PainManagement #FDAApproval #NonOpioid #VertexPharmaceuticals

The Future of Cancer Treatment: A $9 Billion Opportunity Immuno-oncology is set to transform cancer treatment, with therapies like checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines leading the way. By 2030, three BiaTEs (bispecific T-cell engagers) alone could generate $9 billion in sales, signaling a major shift in the relapsed/recurrent multiple myeloma space. According to GlobalData’s survey, 41% of pharmaceutical professionals believe immuno-oncology/cancer therapeutics will drive the strongest innovation pipeline in the next five years. The demand for personalized and effective cancer treatments continues to grow, fueling rapid advancements in this space. Stay ahead of market trends and opportunities. For in-depth insights, get the full report now: https://lnkd.in/gfDXxZBk   Read the full article here: https://lnkd.in/gEe_iyGu #ImmunoOncology #CancerTherapeutics #BiTEs #PharmaceuticalIndustry #HealthcareInnovation